Neurocrine Bio. (NBIX) PT Lowered to $187 at RBC Capital
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $138.94 -0.39%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 70
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 70
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $187.00 (from $198.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Truist Securities Upgrades First Financial Bancorp (FFBC) to Buy
- AGF Management Ltd. (AGF/B:CN) (AGFMF) PT Lowered to Cdn$19 at BMO Capital
- Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
